COPD and concomitant arterial hypertension: The efficacy and safety of slow-release formulation of indapamide

Z. Nersesyan, S. Ovcharenko, T. Morozova (Moscow, Russian Federation)

Source: International Congress 2014 – Clinical presentations
Session: Clinical presentations
Session type: Thematic Poster Session
Number: 3582
Disease area: Airway diseases

Congress or journal article abstractE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Z. Nersesyan, S. Ovcharenko, T. Morozova (Moscow, Russian Federation). COPD and concomitant arterial hypertension: The efficacy and safety of slow-release formulation of indapamide. Eur Respir J 2014; 44: Suppl. 58, 3582

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Safety and long-term efficacy of transition from sildenafil to tadalafil due to side effects in patients with pulmonary arterial hypertension
Source: International Congress 2014 – Modern approach and old dilemmas in lung diseases
Year: 2014

Effects of aclidinium bromide/formoterol fumarate fixed-dose combination on health status in COPD
Source: International Congress 2014 – COPD markers
Year: 2014

Cardio- and cerebrovascular safety of QVA149 in patients with moderate-to-severe COPD: A pooled analysis
Source: International Congress 2014 – Clinical trials of drugs and biomarkers for respiratory diseases
Year: 2014


Association between inhaled corticosteroid use in COPD and incidence or worsening of type2 diabetes
Source: International Congress 2014 – Markers
Year: 2014


Safety of tiotropium and olodaterol fixed-dose combination for COPD in patients on β-blockers
Source: International Congress 2015 – New data on established treatments for COPD
Year: 2015


Efficacy and tolerability of aclidinium bromide/formoterol fumarate fixed-dose combination in patients with COPD: A 1-year study
Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments
Year: 2014

Safety of tiotropium in patients with cardiac events in the TIOSPIR™ trial
Source: International Congress 2015 – Safety of and interactions between current treatments for asthma and COPD
Year: 2015


Once-daily QVA149 has a good safety profile in patients with COPD
Source: Annual Congress 2013 –Clinical trials of LAMAs, LABAs, MABAs and theophylline for asthma and COPD
Year: 2013

Safety of once-daily tiotropium and olodaterol fixed-dose combination via the respimat in chronic obstructive pulmonary disease in two 1-year studies
Source: International Congress 2014 – Asthma and COPD devices and treatments
Year: 2014


Clinical efficacy of oral sildenafil therapy in the treatment of pulmonary hypertension
Source: Eur Respir J 2007; 30: Suppl. 51, 347s
Year: 2007

Comparison of indacaterol with tiotropium or once-daily dual long-acting bronchodilator therapy with roflumilast for severe COPD
Source: International Congress 2014 – Markers
Year: 2014

Clinical and inhaled drug profile of COPD patients with indication for beta-blockers who are on beta-blockers
Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings
Year: 2013


Long-term safety of a new formulation of epoprostenol in pulmonary arterial hypertension
Source: Annual Congress 2013 –Pulmonary circulation: clinical diagnosis, imaging, biomarkers and treatment
Year: 2013

Efficacy of tiotropium and olodaterol fixed-dose combination in patients with COPD on β-blockers
Source: International Congress 2015 – Safety of and interactions between current treatments for asthma and COPD
Year: 2015


Roflumilast added to triple therapy in severe COPD patients with frequent exacerbations: Efficacy and tolerability
Source: International Congress 2014 – Markers
Year: 2014

Safety and efficacy of bosentan in combination with sildenafil in pulmonary arterial hypertension: The COMPASS-3 study
Source: Annual Congress 2011 - Treatments for pulmonary hypertension in human and experimental models
Year: 2011


Comparative assessment of umeclidinium/vilanterol (UMEC/VI) combination therapy among symptomatic COPD patients
Source: International Congress 2014 – Asthma and COPD management
Year: 2014

Effectiveness and safety of concurrent beta-blockers and inhaled bronchodilators in COPD with cardiovascular comorbidities
Source: Eur Respir Rev, 26 (145) 160123; 10.1183/16000617.0123-2016
Year: 2017



Efficacy and safety of aclidinium/formoterol fixed-dose combination in patients with moderate to severe airflow obstruction, stratified by severity
Source: International Congress 2015 – New data on established treatments for COPD
Year: 2015


Prognostic factors of mortality and cardiovascular outcomes in the tiotropium safety and performance in respimat (TIOSPIR) trial
Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments
Year: 2014